Avinger

Avinger, Inc. is a commercial-stage medical device company, which engages in the designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral artery disease. Its products include Pantheris, Lightbox, Ocelot, Wildcat, Juicebox, and Kittycat. The company was founded by John B. Simpson and Himanshu N. Patel on March 8, 2007 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avinger reports Q1 revenue growth, secures China partnership for expansion

Avinger's Q1 2024 performance showed revenue growth but challenges in profitability.
Strategic partnerships and product development present growth opportunities.
Financial restructuring and cost management are crucial for future success.

Avinger reports improved Q3 performance and strategic growth initiatives

Avinger's Q3 2024 performance showed operational improvements and cost-saving initiatives, leading to reduced losses.
The company's strategic partnerships and focus on innovation position them for growth opportunities in the medical device market.
While challenges persist, Avinger's progress in commercialization and partnerships signal a path towards financial stability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

REDWOOD CITY, CA / ACCESSWIRE / August 16, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced presentations featuring the Company's Lumivascular, OCT-guided, technologies at the annual AMP (Amputation Prevention Symposium) conference occurring last week. AMP focuses on education and technologies for treating critical limb ischemia (CLI), an advanced stage of PAD, in patients facing a life-altering amputation.

Avinger OCT-Guided Technologies Featured at AMP 2021

Avinger, Inc. (AVGR) CEO Jeff Soinski on Q2 2021 Results - Earnings Call Transcript

Shares of Avinger (NASDAQ:AVGR) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 77.78% year over year to ($0.04), which were in line with the estimate of ($0.04).

Avinger: Q2 Earnings Insights

Pantheris Sales and Tigereye™ Expansion Drive 91% Year-Over-Year Revenue Growth REDWOOD CITY, CA / ACCESSWIRE / August 10, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights Revenue increased 91% year-over-year to $2.8 million, fueled by Pantheris sales growth and new Tigereye CTO sales Record Pantheris SV revenue reflects strong market adoption of Avinger's small-vessel catheter, primarily used in below-the-knee (BTK) applications Image-guided CTO revenue increased 114% year-over-year, driven by Tigereye launch at more than 40 sites Gross margin increased to 36% as Avinger scales its operations Opened more than 30 new Lumivascular accounts in the last 12 months on increased market demand for Avinger's highly differentiated technology Filed 510(k) in June to expand Pantheris clinical indication for treatment of in-stent restenosis (ISR) Filed 510(k) in August for the Lightbox 3 next generation imaging console Maintained strong cash position of $26.7 million at June 30, 2021, anticipated to fund sales force expansion, new product development and clinical plans through 2022 Jeff Soinski, Avinger's President and CEO, commented, "Avinger's 2021 growth momentum continued in the second quarter as we delivered strong revenue gains for both our Pantheris atherectomy and image-guided CTO product lines and procedural volume improving in the first half of the year.

Avinger Reports Second Quarter 2021 Financial Results

Avinger (NASDAQ:AVGR) releases its next round of earnings this Tuesday, August 10. Here is Benzinga's essential guide to Avinger's Q2 earnings report.

Earnings Outlook For Avinger

Smaller Footprint, Improved User Experience and Lower Cost to Drive Adoption REDWOOD CITY, CA / ACCESSWIRE / August 9, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for its new Lightbox 3 imaging console. "Avinger's Lightbox 3 represents an important leap forward in imaging, portability and capability," commented Jeff Soinski, Avinger's President and CEO.

Avinger Announces 510(k) Filing for New Lightbox 3 Imaging Console

REDWOOD CITY, CA / ACCESSWIRE / July 27, 2021 / Avinger, Inc. (Nasdaq:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2021 after the close of trading on Tuesday, August 10, 2021. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

Avinger to Announce Second Quarter 2021 Results on August 10, 2021

Avinger Inc (NASDAQ: AVGR) has submitted a 510(k) application to the FDA for a new Pantheris clinical indication for the treatment of in-stent restenosis (ISR) in the lower extremity arteries. To submission is based on the INSIGHT trial that evaluated the safety and effectiveness of the Pantheris atherectomy system for treating in-stent restenosis in lower extremity arteries.

Avinger Files US Application For New Pantheris In-Stent Restenosis Indication

REDWOOD CITY, CA / ACCESSWIRE / July 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the submission of a 510(k) application to the U.S. Food & Drug Administration (FDA) for a new Pantheris clinical indication for the treatment of in-stent restenosis (ISR) in the lower extremity arteries. Highlighting the importance of this submission, Jeff Soinski, Avinger's President and CEO commented, "We are extremely pleased with this milestone and the initial clinical data generated from the INSIGHT trial that supports the 510(k) submission.

Avinger Announces 510(k) Filing for New Pantheris In-Stent Restenosis Indication

Cemex SAB de CV

Mogo

Comscore Inc.

Enthusiast Gaming Holdings

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

5 Red-Hot Stocks Under $10 With Big Upside Potential

Borr Drilling Ltd

Borqs Technologies

Federal Home Loan Mortgage Corporation

Inpixon

Inuvo

Predictive Oncology Inc

Which penny stocks are investors watching with inflation on the rise? Here's 7 for your list The post Hot Penny Stocks to Buy to Avoid Inflation?

Hot Penny Stocks to Buy to Avoid Inflation? 7 For Your July Watchlist

The stock price of Avinger Inc (NASDAQ: AVGR) increased by over 16% during intraday trading. This is why it happened.

AVGR Stock Price Increases Over 16%: Why It Happened

REDWOOD CITY, CA / ACCESSWIRE / June 28, 2021 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced key opinion leader (KOL) presentations featuring the company's Lumivascular technology at two important vascular conferences held in Germany: the annual German CLI Congress and the Essen Vascular Conference. Dr. Arne Schwindt, a vascular surgeon from St. Franziskus Hospital Münster in Germany, gave a presentation featuring Avinger's Lumivascular technology at the annual Critical Limb Ischemia (CLI) Congress in Germany.

Avinger Announces Key Opinion Leader Presentations at Vascular Conferences in Germany

REDWOOD CITY, CA / ACCESSWIRE / May 25, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the issuance and allowance of seven U.S. patents to date in 2021. These new U.S. patents include a wide range of claims relating to Avinger's proprietary optical coherence tomography (OCT) intravascular imaging system and its OCT-guided catheters for the treatment of vascular disease.

Avinger Announces Issuance and Allowance of Seven U.S. Patents

REDWOOD CITY, CA / ACCESSWIRE / May 17, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its management will host investor meetings on May 26, 2021 as part of the Oppenheimer MedTech, Tools & Diagnostics Summit. Institutional investors that wish to schedule a meeting with management can contact their Oppenheimer sales representative or Matt Kreps, Investor Relations for Avinger, at mkreps@darrowir.com.

Avinger To Present at the Oppenheimer MedTech, Tools & Diagnostics Summit May 26

Avinger, Inc. (AVGR) CEO Jeff Soinski on Q1 2021 Results - Earnings Call Transcript

13% Year-over-Year Revenue Growth Driven by Tigereye™ Commercial Launch and Pantheris SV Sales Growth REDWOOD CITY, CA / ACCESSWIRE / May 6, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported results for the first quarter ended March 31, 2021. First Quarter and Recent Highlights Revenue increased 13% year-over-year to $2.6 million, reflecting commercial launch of the new Tigereye™ CTO-crossing device and strong Pantheris SV sales growth Gross margin improved 13 percentage points year-over-year to 35%, driven by increased volume as Avinger continues to scale its operations Progressed Tigereye to full commercial launch in January 2021, with more than 30 accounts utilizing the device Image-guided CTO revenue increased 62% year-over-year, driven by early success of the Tigereye launch Shipped record number of Pantheris SV devices as sites continue to increase adoption of Avinger's highly differentiated small-vessel catheter Opened 8 new Lumivascular accounts in the first quarter, following the launch of 9 new accounts in the fourth quarter of 2020 Extended the maturity date of Avinger's existing loan agreement to 2025 Increased cash to $30.4 million at March 31, 2021, anticipated to fully fund sales expansion, new product development and clinical plans through 2022 Jeff Soinski, Avinger's President and CEO, commented, "This year is off to a strong start as Avinger reported substantial growth in our first quarter results over the prior year.

Avinger Reports First Quarter 2021 Financial Results

CASI Pharmaceuticals

Remark Hlds

Penny stocks to buy according to top Wall Street analysts The post 3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Hot Penny Stocks To Buy With Analysts Expecting Up To 383%

REDWOOD CITY, CA / ACCESSWIRE / April 26, 2021 / Avinger, Inc. (NASDAQ:AVGR), commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2021 after the close of trading on Thursday, May 6, 2021. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.

Avinger to Announce First Quarter 2021 Results on May 6, 2021

GT Biopharma Inc

Senseonics Holdings

List Of Penny Stocks To Watch Right Now The post Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks To Watch In April 2021 If Biotech Is A Focus

REDWOOD CITY, CA / ACCESSWIRE / April 21, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the publication of two clinical studies in peer-reviewed journals, further supporting the clinical benefits of its therapeutic devices. The studies were based on separate clinical case series conducted by physicians at the Division of Cardiovascular Disease and Endovascular Medicine at the Einstein Medical Center in Philadelphia, Pennsylvania.

New Publications Highlight Clinical Benefits of Avinger PAD Therapies

REDWOOD CITY, CA / ACCESSWIRE / April 15, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today reported that more than 100 accounts have purchased Pantheris SV OCT-guided atherectomy catheters for the treatment of PAD since product launch in the third quarter of 2019. "By combining real-time intravascular imaging with the precise control of directional atherectomy, our Pantheris SV device is proving to be an optimal choice for the treatment of peripheral artery disease in small vessels," commented Jeff Soinski, Avinger's President and CEO.

Avinger Achieves Commercial Milestone with More Than 100 Accounts Using Pantheris SV

REDWOOD CITY, CA / ACCESSWIRE / April 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today provided an update on the commercial launch of Tigereye CTO Crossing catheters for the treatment of PAD. Following limited launch in the fourth quarter of 2020, Avinger initiated full commercial launch of Tigereye in January 2021.

Avinger Provides Update on Tigereye(TM) Commercial Launch

It's been reported that AVGR stock is popular among Robinhood traders. That's fine, but it's more important to see the company's potential.

Target Top-Line Growth and Compelling Patient Outcomes with Avinger

Avinger, Inc. (AVGR) CEO Jeff Soinski on Q4 2020 Results - Earnings Call Transcript

News for Avinger Stock (AVGR)